In 2020, the European Commission stressed the importance of continuously monitoring the safety and effectiveness of vaccines in the EU/EEA during the post-authorisation phase, with particular emphasis on COVID-19 vaccines in the context of the ongoing pandemic.
This document describes how to strengthen surveillance in hospital settings for the identification of severely affected patients infected with avian influenza virus in the EU/EEA.
The purpose of this guide is to complement the handbook published in 2014 by offering practical, operational
guidance on how to design, develop, conduct and evaluate tabletop and functional exercises.
This assessment tool, which will be used during the country visits to Western Balkans and Türkiye, aims to provide ECDC with a good understanding of national communicable disease surveillance systems.
High levels of community transmission and the co-circulation of respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, respiratory syncytial virus (RSV) and others can increase pressure on healthcare systems.
This document aims to provide guidance for public health and laboratory experts in identifying human infections with animal influenza viruses as early as possible to provide early warning and inform risk assessments and public health measures.
This Reporting Protocol contains guidelines on how to prepare data for submission to TESSy, deadlines for data submission, subject-specific information, and links to further information.
This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.
This document outlines operational considerations to support the continuity of national surveillance systems and public health laboratories for epidemiological and virological surveillance for influenza, SARS-CoV-2, and potentially other respiratory viruses in the 2022/2023 winter season and beyond.
This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.